{"id":90861,"date":"2019-12-02T08:47:13","date_gmt":"2019-12-02T13:47:13","guid":{"rendered":"https:\/\/pulmonx.com\/stratx\/"},"modified":"2026-05-04T12:09:46","modified_gmt":"2026-05-04T17:09:46","slug":"stratx","status":"publish","type":"page","link":"https:\/\/pulmonx.com\/uk-en\/stratx\/","title":{"rendered":"StratX"},"content":{"rendered":"

<\/p>\n\n

\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n \n
\n
\n \"Pulmonx-Zephyr-Clinically-Proven\" \n <\/div>\n \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n
\n
\n

StratX\u00ae<\/sup> Lung Analysis Report<\/h1>\n

Treat with Confidence<\/strong><\/h2> <\/div>\n<\/div>\n
\n
\n \n
\n
\n \"StratX-Report-Numbers-01\" \n <\/div>\n \n \n <\/div>\n <\/div>\n
\n \n
\n
\n
\n
\n
\n
\n

A cloud-based quantitative CT analysis service that supports Zephyr\u00ae<\/sup> Valve patient selection and treatment targeting by providing information on emphysema destruction, fissure completeness, and lobar volumes.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n\n

\n
\n
\n
\n
\n
\n

Zephyr Valve treatment is the most rigorously studied minimally\u2013invasive<\/strong> treatment for severe emphysema and is clinically proven to improve patients\u2019 breathing function, exercise capacity,<\/strong> and quality of life.<\/strong>1-3<\/sup><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n \n
\n
\n
\n
\n
\n
\n

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n \n
\n
\n
\n
\n
\n
\n

Lung Report Interpretation<\/strong><\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n
\n
\n \n
\n
\n

\"\"Summary<\/strong><\/h3>\n

The goal of Zephyr Endobronchial Valve treatment is to completely occlude and reduce the volume of a target lobe, thereby improving hyperinflation and breathing dynamics. In selecting a target lobe, physicians should look for higher levels of emphysema destruction and presence of complete or nearly complete fissures with neighbouring lobes (which has been associated with absence of collateral ventilation and likely response to therapy).18<\/sup><\/a><\/p>\n

The StratX Lung Report contains tabulated data on fissure completeness by lobe, destruction score by lobe, and lobar volume. An infographic \u201ckey\u201d for easy interpretation of the data is also included. This infographic includes colour coding representing the level of emphysema destruction (with darker colours representing lobes with more destruction) and different levels of fissure completeness relative to a target lobe (with darker and more complete lines having greater completeness).<\/p> <\/div>\n<\/div>\n\n

\n
\n
\n
\n
\n
\n

StratX Reports provide fissure completeness, emphysema density, and inspiratory volumes to allow identification of target lobes that are good candidates for treatment with Zephyr Valves.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n<\/div>\n <\/div>\n

\n \n
\n
\n

\"\"Fissure Completeness<\/strong><\/h3>\n

Fissure completeness has been shown to be a predictor of success for Zephyr Valve therapy as it indicates absence of collateral ventilation between the target and the neighbouring lobes.19<\/sup><\/a><\/p>\n

The StratX Lung Report displays fissure completeness values \u201cby lobe,\u201d i.e., the values are computed as a percentage of the total area of the fissure across the lobar boundary. The fissure completeness between each lobar region is represented with a dark solid, light solid, or dotted line. The dark solid line represents fissures that are \u226595% intact.<\/p>\n

The light solid line represents fissures that are 80-95% intact. The dotted line represents fissures which are below 80% intact. A fissure completeness score of <80% indicates the presence of collateral ventilation in that lobe and the lobe should not be considered for treatment with Zephyr Valves. For fissure completeness scores of >80%, fissure integrity should be confirmed using Pulmonx\u2019s Chartis\u00ae<\/sup> Pulmonary Assessment System to ensure that the target lobe is negative for collateral ventilation.<\/p> <\/div>\n<\/div>\n <\/div>\n <\/div>\n

\n
\n \n
\n
\n
\n
\n
\n
\n

\"\"<\/p>\n

\n
\n
\n
\n

Destruction Scoring<\/strong><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

Destruction scoring is calculated as the percentage
of voxels in Hounsfield units in a lobe that fall below a threshold value. For example, if the total number of voxels in the lobe was 1000, and 800 voxels fell below the threshold of -910 HU, the \u201cdestruction score\u201d for that lobe at -910 HU would be 80%.<\/p>\n

Lobar Destruction Score values of greater than 50% at -910 HU have been commonly used as an inclusion criterion for various clinical trials of Zephyr Valve therapy.1-3<\/sup><\/a><\/p>\n

In the report and summary view, the degree of shading of a lobe and the numbers within the lobe represent the level of destruction; lobes with less than 50% destruction are coloured white and are usually not considered as potential targets. Percent destruction scores below -950 HU are also provided for reference.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n <\/div>\n

\n \n
\n
\n
\n
\n
\n
\n

\"\"<\/p>\n

\n
\n
\n
\n

Inspiratory Volume<\/strong><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

The inspiratory volume represents the volume of each lobe in millilitres. The inspiratory volume can help to identify the lobes with the largest volume representing hyperinflation and ones that may be a good target for Zephyr Valve treatment.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n\n

\n
\n
\n
\n
\n
\n

While the summary section provides a good quick reference, the actual values in the results table should be reviewed before making a decision on which lobe(s) to target.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n \n
\n
\n
\n
\n
\n
\n

Features a user-friendly design<\/strong> for clear interpretation and ease of use<\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n<\/div>\n <\/div>\n
\n \n
\n
\n \"Pulmonx-Patient-Selection-StratX-Report-Analysis\" \n <\/div>\n \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

StratX Report Features<\/strong><\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n\n
\n
\n
\n
\n
\n
\n

The StratX Lung Analysis Report Enables You To:<\/strong><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n<\/div>\n
\n
\n \n
\n
\n
\n
\n
\n
\n